$170 Million is the total value of Tamarack Advisers, LP's 46 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 63.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $10,433,000 | +27.9% | 685,000 | +24.5% | 6.13% | +29.8% |
| PCRX | Buy | PACIRA BIOSCIENCES INCequity | $10,372,000 | +1.7% | 195,000 | +11.4% | 6.09% | +3.2% |
| PRGO | Buy | PERRIGO CO PLCequity | $9,093,000 | +12.1% | 255,000 | +27.5% | 5.34% | +13.7% |
| THC | Buy | TENET HEALTHCARE CORPequity | $9,027,000 | +7.3% | 175,000 | +9.4% | 5.30% | +8.9% |
| CERS | Buy | CERUS CORPequity | $8,730,000 | -17.5% | 2,425,000 | +21.2% | 5.13% | -16.3% |
| ANGO | Buy | ANGIODYNAMICS INCequity | $6,650,000 | +7.4% | 325,000 | +1.6% | 3.90% | +9.0% |
| PHR | Buy | PHREESIA INCequity | $6,625,000 | +8.1% | 260,000 | +6.1% | 3.89% | +9.7% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INCequity | $6,019,000 | +142.1% | 71,000 | +136.7% | 3.53% | +145.8% |
| SNY | Buy | SANOFI-ADRdepository receipt | $5,893,000 | +24.0% | 155,000 | +63.2% | 3.46% | +25.8% |
| STRM | New | STREAMLINE HEALTH SOLUTIONSequity | $5,868,000 | – | 4,930,882 | +100.0% | 3.44% | – |
| VTRS | Buy | VIATRIS INCequity | $5,538,000 | +51.1% | 650,000 | +85.7% | 3.25% | +53.4% |
| COLL | Buy | COLLEGIUM PHARMACEUTICAL INCequity | $4,806,000 | +171.2% | 300,000 | +200.0% | 2.82% | +175.3% |
| CVS | New | CVS HEALTH CORPequity | $4,769,000 | – | 50,000 | +100.0% | 2.80% | – |
| ALKS | New | ALKERMES PLCequity | $4,466,000 | – | 200,000 | +100.0% | 2.62% | – |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLCequity | $3,999,000 | +2.5% | 30,000 | +20.0% | 2.35% | +4.1% |
| Buy | DOCGO INCequity | $3,720,000 | +197.6% | 375,000 | +114.3% | 2.18% | +202.1% | |
| ICUI | Buy | ICU MEDICAL INCequity | $2,259,000 | +5.7% | 15,000 | +15.4% | 1.33% | +7.3% |
| MOH | New | MOLINA HEALTHCARE INCequity | $1,979,000 | – | 6,000 | +100.0% | 1.16% | – |
| IQV | New | IQVIA HOLDINGS INCequity | $1,811,000 | – | 10,000 | +100.0% | 1.06% | – |
| TCMD | Buy | TACTILE SYSTEMS TECHNOLOGY Iequity | $1,753,000 | +37.2% | 225,000 | +28.6% | 1.03% | +39.2% |
| PLXS | Buy | PLEXUS CORPequity | $1,751,000 | +271.8% | 20,000 | +233.3% | 1.03% | +277.9% |
| FENC | New | FENNEC PHARMACEUTICALS INCequity | $1,418,000 | – | 175,000 | +100.0% | 0.83% | – |
| RDNT | Buy | RADNET INCequity | $1,221,000 | +41.3% | 60,000 | +20.0% | 0.72% | +43.4% |
| BIO | New | BIO-RAD LABORATORIES-Aequity | $834,000 | – | 2,000 | +100.0% | 0.49% | – |
| NVST | New | ENVISTA HOLDINGS CORPequity | $820,000 | – | 25,000 | +100.0% | 0.48% | – |
| Buy | DERMTECH INCequity | $693,000 | +25.1% | 175,000 | +75.0% | 0.41% | +26.8% | |
| New | BDX US 10/21/22 P260put | $680,000 | – | 200 | +100.0% | 0.40% | – | |
| New | MAXCYTE INCequity | $534,000 | – | 82,099 | +100.0% | 0.31% | – | |
| New | SPY US 10/03/22 P350put | $125,000 | – | 2,500 | +100.0% | 0.07% | – | |
| Buy | TLT US 11/18/22 C125call | $76,000 | -76.1% | 4,000 | +60.0% | 0.04% | -75.5% | |
| New | VTRS US 10/21/22 C12call | $30,000 | – | 4,000 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.